Skip to main content
Premium Trial:

Request an Annual Quote

Intradigm Develops siRNA SARS Inhibitor

NEW YORK, Sept. 5 (GenomeWeb News) - Intradigm announced today that it had developed siRNA capable of achieving 90 percent inhibition of the SARS virus in cell-based studies.

 

The Rockville, Md.-based RNAi company collaborated with Qiagen to design the siRNA, which targeted specific genes throughout the SARS genome. Qiagen synthesized the siRNA, and the product was tested in laboratories in Hong Kong and Guangzhou, China using non-human primate cells exposed to the SARS virus. Hong Kong-based Top Biotech sponsored the effort along with the provincial government of Guangdong province, China. Scientists from GuangzhouMedicalUniversity and Zhongshan University of Guangzhou, as well as Hong KongUniversity also worked on the project.

 

Intradigm has already established a collaboration with scientists from the National Institute of Allergy and Infectious Diseases in the US, and from institutions in Hong Kong and Guangzhou to develop siRNA-based anti-SARS therapies.

 

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.